Nordic Pharma has announced the introduction of Lacrifill®, a novel therapy for dry eye, to the European market. Following CE mark approval in 2025, Lacrifill® is now available to healthcare professionals and patients across a range of European markets.
Lacrifill® is a cross-linked hyaluronic acid gel designed to temporarily block tear drainage by physiologically occluding the canalicular system. By enhancing tear film preservation, it helps maintain natural lubricating tears on the patients’ ocular surface, offering an individualized approach to dry eye management. The in-office procedure provides a full fill of the canalicular system and delivers long-lasting effects for up to six months.
Dry eye disease is a highly prevalent condition, affecting up to 30% of the European population and represents a particular challenge in patients undergoing ocular surgical procedures. Pre-existing ocular surface disease in candidates for cataract or LASIK surgery can compromise surgical outcomes and impact patient satisfaction.
“Achieving a stable ocular surface is a vital prerequisite for successful surgical outcomes. The introduction of Lacrifill® to the European market is a welcome development, providing us with a new tool for pre-and post-operative ocular surface health optimization and ensuring our patients have access to the latest advancements in ocular care” said Professor Jose Benitez del Castillo of Complutense University of Madrid, Spain.
“The European launch of Lacrifill® represents a significant milestone for Nordic Pharma” said Charlotte Phelps, CEO of Nordic Group B.V. “We are proud to bring this innovative dry eye therapy to patients and healthcare professionals across Europe, and we believe it will help many of those currently living with dry eye disease and become an important addition to dry eye management, particularly around ocular surgery.”
